ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation

• Egile Nagusiak: Jing Cheng (Egilea), Fei Xue (Egilea), Cheng Cheng (Egilea), Wenhai Sui (Egilea), Meng Zhang (Egilea), Lei Qiao (Egilea), Jing Ma (Egilea), Xiaoping Ji (Egilea), Wenqiang Chen (Egilea), Xiao Yu (Egilea), Bo Xi (Egilea), Feng Xu (Egilea), Guohai Su (Egilea), Yuxia Zhao (Egilea), Panpan Hao (Egilea), Yun Zhang (Egilea), Cheng Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

A disintegrin and metalloprotease domain family protein 17 (ADAM17) is a new member of renin-angiotensin system (RAS) but its role in the pathogenesis of diabetic cardiomyopathy (DCM) is obscure. To test the hypothesis that ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fi...